Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to -$22.6 million.

  • Vanda Pharmaceuticals' Net Income towards Common Stockholders fell 324.23% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 413.85%. This contributed to the annual value of -$18.9 million for FY2024, which is 853.29% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Net Income towards Common Stockholders of -$22.6 million as of Q3 2025, which was up 16.92% from -$27.2 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $9.6 million for Q2 2021, and its period low was -$29.5 million during Q1 2025.
  • In the last 3 years, Vanda Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$4.5 million in 2024 and averaged -$8.7 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Net Income towards Common Stockholders spiked by 1,856.46% in 2021, and later plummeted by 3,057.78% in 2024.
  • Quarterly analysis of 5 years shows Vanda Pharmaceuticals' Net Income towards Common Stockholders stood at $7.1 million in 2021, then decreased by 2.96% to $6.9 million in 2022, then plummeted by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then crashed by 324.23% to -$22.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$22.6 million in Q3 2025, compared to -$27.2 million in Q2 2025 and -$29.5 million in Q1 2025.